Transplanted bone marrow-derived mononuclear cells (BMMNCs) can promote arteriogenesis and angiogenesis by incorporating into vascular walls and differentiating into smooth muscle cells (SMCs) and endothelial cells (ECs). Here, we explored whether BMMNCs can enhance arteriogenesis and angiogenesis and promote long-term functional recovery in a rat model of permanent middle cerebral artery occlusion (pMCAO). Sprague-Dawley rats were injected with vehicle or 1 Â 10 7 BMMNCs labeled with BrdU via femoral vein 24 h after induction of pMCAO. Functional deficits were assessed weekly through day 42 after pMCAO, and infarct volume was assessed on day 7. We visualized the angioarchitecture by latex perfusion on days 14 and 42. BMMNC transplantation significantly reduced infarct volume and neurologic functional deficits compared with untreated or vehicle-treated ischemic groups. In BMMNC-treated rats, BrdU-positive cells were widely distributed in the infarct boundary zone, were incorporated into vessel walls, and enhanced the growth of leptomeningeal anastomoses, the circle of Willis, and basilar arteries. BMMNCs were shown to differentiate into SMCs and ECs from day 14 after stroke and preserved vascular repair function for at least 6 weeks. Our data indicate that BMMNCs can significantly enhance arteriogenesis and angiogenesis, reduce infarct volume, and promote long-term functional recovery after pMCAO in rats.
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Introduction
After ischemic stroke, blood supply to the injured brain is decreased, leading to dysfunction of the brain tissue in that area. This type of stroke is usually precipitated by progressive atherosclerosis or an embolus from the heart or neck vessels (Shuaib et al., 2011) . The only treatment currently available for ischemic stroke is thrombolytic therapy. However, it would be very beneficial to be able to restore anterograde perfusion of the ischemic territory through arterial revascularization (Bang et al., 2011; Shuaib et al., 2011) .
The circle of Willis, leptomeningeal anastomoses, and microvasculature in the peri-infarction zone are important paths of collateral perfusion for the injured brain tissue (Carmeliet and Jain, 2011; Shuaib et al., 2011) . Promoting additional collateral circulation may represent a potential treatment for ischemic stroke (Carmeliet and Jain, 2011; Shuaib et al., 2011) . Collateral vessels bring bulk flow to ischemic cerebral tissues and may be sufficient to replace the stroke-induced loss of perfusion (Bang et al., 2011; Shuaib et al., 2011) . Establishment of collateral circulation and new capillaries can be achieved by neovasculogenesis, which refers to the development of a new vascular network and comprises two different processes: arteriogenesis and angiogenesis (Ruiz-Salmeron et al., 2011; Troidl and Schaper, 2012) . Arteriogenesis occurs when preexisting collateral arterioles transform into functional collateral arteries, whereas angiogenesis is the expansion of the vascular network via sprouting in the ischemic border (Carmeliet and Jain, 2011; Sugiyama et al., 2011) . Evidence suggests that therapeutic arteriogenesis and angiogenesis can be stimulated by cell transplantation (Hao et al., 2011; Imada et al., 2005; Li et al., 2011; Ruiz-Salmeron et al., 2011; Yoon et al., 2010) .
One cell type that might be useful for promoting collateral vessel growth through autologous or allogeneic transplantation is the bone marrow mononuclear cell (BMMNC). The arteriogenic effects of BMMNCs have been confirmed in limb ischemia and myocardial infarction (Imada et al., 2005; Li et al., 2011; Ruiz-Salmeron et al., 2011; Yoon et al., 2010) . Transplanted BMMNCs also have been shown to cross the blood-brain barrier and to convert into neuronal and glial cell types in a cerebral ischemic animal model (Iihoshi et al., 2004; Zhang et al., 2011) . Additionally, BMMNCs can
